{"id":"fmx-103-1-5","_chembl":{"chemblId":"CHEMBL3682147","moleculeType":"Small molecule","molecularWeight":"412.50"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"Minocycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Beyond its antimicrobial activity against Cutibacterium acnes, minocycline exhibits anti-inflammatory properties that may help reduce acne lesions and inflammation.","oneSentence":"Topical minocycline formulation that provides anti-inflammatory and antimicrobial effects through inhibition of bacterial protein synthesis and modulation of inflammatory pathways."},"_scrapedAt":"2026-03-28T03:32:23.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123859,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"clindamycin phosphate","brand":"Cleocin-T","company":null,"rationale":"Topical antibiotic for acne treatment"},{"name":"dapsone","brand":"Aczone","company":"Allergan","rationale":"Topical anti-inflammatory for acne"},{"name":"sarecycline","brand":"Seysara","company":"Almirall","rationale":"Oral tetracycline-class antibiotic for moderate-to-severe acne"}],"description":"FMX-103 1.5% is an investigational topical minocycline foam formulation developed by Vyne Therapeutics for the treatment of moderate-to-severe acne vulgaris. The product utilizes Vyne's proprietary foam technology to deliver minocycline directly to the skin, potentially offering anti-inflammatory and antimicrobial benefits.","indications":{"approved":[{"status":"investigational","condition":"Acne vulgaris (moderate-to-severe)","patientPopulation":"Adult and adolescent patients"}]},"trialDetails":[{"nctId":"NCT03276936","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-09-05","conditions":"Papulopustular Rosacea","enrollment":504},{"nctId":"NCT03142451","phase":"PHASE3","title":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-02","conditions":"Facial Papulopustular Rosacea","enrollment":751},{"nctId":"NCT04608500","phase":"PHASE3","title":"A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-01","conditions":"Facial Papulopustular Rosacea","enrollment":771},{"nctId":"NCT02601963","phase":"PHASE2","title":"Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2015-09","conditions":"Rosacea, Papulopustular Rosacea","enrollment":233}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":454919,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Minocycline foam 1.5%"],"phase":"phase_2","status":"active","brandName":"FMX-103 1.5%","genericName":"FMX-103 1.5%","companyName":"Vyne Therapeutics Inc.","companyId":"vyne-therapeutics-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}